{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:53:00Z","timestamp":1793980380140,"version":"4.8.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1043149"],"award-info":[{"award-number":["1043149"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1016701"],"award-info":[{"award-number":["1016701"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1113133"],"award-info":[{"award-number":["1113133"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["7001-013"],"award-info":[{"award-number":["7001-013"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["7015-18"],"award-info":[{"award-number":["7015-18"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>BH3 mimetic drugs that selectively target the pro-survival BCL2 proteins are highly promising for cancer treatment, most notably for treating blood cancers. Venetoclax, which inhibits BCL2, is now approved for treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Preferably, robust and validated assays would identify patients most likely to benefit from therapy with venetoclax itself or with inhibitors of other pro-survival proteins. A sophisticated method that has been developed is the BH3 profiling assay. In this assay, permeabilized, instead of intact, cells are treated for a few hours with inhibitors of the pro-survival BCL2 proteins, and the resultant mitochondrial depolarization measured. Sensitivity to a specific inhibitor (e.g., venetoclax or other BH3 mimetics) is then used to infer the reliance of a tumor (e.g., CLL) on one or more pro-survival BCL2 proteins. However, we found that this methodology cannot reliably identify such dependencies. In part, this is because almost all cells express multiple pro-survival BCL2 proteins that restrain BAX and BAK which must be inhibited before mitochondrial depolarization and apoptosis can proceed. Using genetic and pharmacological tools across multiple cell line models of blood cancer, we demonstrated that selective BCL2 inhibitors have important flow-on effects that includes the redistribution of BH3-only proteins to ancillary pro-survival proteins not directly engaged by the inhibitor. These secondary effects, critical to the biological action of selective inhibitors, were not accurately recapitulated in permeabilized cells, probably due to the limited time frame possible in such assays or the altered biophysical conditions when cells are permeabilized. While we could consistently define the sensitivity of a tumor cell to a particular BH3 mimetic drugs using intact cells, this was not reliable with permeabilized cells. These studies emphasize the need to carefully evaluate assays on permeabilized cells undertaken with inhibitors of the pro-survival BCL2 proteins.<\/jats:p>","DOI":"10.1038\/s41418-025-01487-7","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:21:31Z","timestamp":1744204891000},"page":"1382-1396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4977-9775","authenticated-orcid":false,"given":"Jia-Nan","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tirta M.","family":"Djajawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1076-3496","authenticated-orcid":false,"given":"Donia M.","family":"Moujalled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Pomilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Khong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale L.","family":"Fedele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Riffkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8033-9140","authenticated-orcid":false,"given":"Christine A.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1193-8147","authenticated-orcid":false,"given":"Guillaume","family":"Lessene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7539-7581","authenticated-orcid":false,"given":"Marco J.","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5020-4891","authenticated-orcid":false,"given":"Andreas","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Grigoriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3866-4318","authenticated-orcid":false,"given":"Mark F.","family":"van Delft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-5720","authenticated-orcid":false,"given":"Andrew W.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3101-4873","authenticated-orcid":false,"given":"David C. S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"1487_CR1","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood.2020006785","volume":"138","author":"AW Roberts","year":"2021","unstructured":"Roberts AW, Wei AH, Huang DCS. BCL2 and MCL1 inhibitors for hematologic malignancies. Blood. 2021;138:1120\u201336.","journal-title":"Blood"},{"key":"1487_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175\u201393.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1487_CR3","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1158\/2159-8290.CD-21-1334","volume":"12","author":"J Montero","year":"2022","unstructured":"Montero J, Haq R. Adapted to survive: targeting cancer cells with BH3 mimetics. Cancer Discov. 2022;12:1217\u201332.","journal-title":"Cancer Discov"},{"key":"1487_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","volume":"22","author":"ST Diepstraten","year":"2022","unstructured":"Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2022;22:45\u201364.","journal-title":"Nat Rev Cancer"},{"key":"1487_CR5","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1182\/blood.V79.11.2981.2981","volume":"79","author":"M Schena","year":"1992","unstructured":"Schena M, Larsson LG, Gottardi D, Gaidano G, Carlsson M, Nilsson K, et al. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood. 1992;79:2981\u20139.","journal-title":"Blood"},{"key":"1487_CR6","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","volume":"82","author":"M Hanada","year":"1993","unstructured":"Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 1993;82:1820\u20138.","journal-title":"Blood"},{"key":"1487_CR7","first-page":"456","volume":"10","author":"LE Robertson","year":"1996","unstructured":"Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996;10:456\u20139.","journal-title":"Leukemia"},{"key":"1487_CR8","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1182\/blood.V91.9.3379","volume":"91","author":"S Kitada","year":"1998","unstructured":"Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood. 1998;91:3379\u201389.","journal-title":"Blood"},{"key":"1487_CR9","doi-asserted-by":"publisher","first-page":"13944","DOI":"10.1073\/pnas.0506654102","volume":"102","author":"A Cimmino","year":"2005","unstructured":"Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102:13944\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1487_CR10","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1038\/leu.2009.151","volume":"23","author":"KD Mason","year":"2009","unstructured":"Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie WD, et al. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia. 2009;23:2034\u201341.","journal-title":"Leukemia"},{"key":"1487_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1172\/JCI28281","volume":"117","author":"V Del Gaizo Moore","year":"2007","unstructured":"Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Investig. 2007;117:112\u201321.","journal-title":"J Clin Investig"},{"key":"1487_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl J Med. 2016;374:311\u201322.","journal-title":"N. Engl J Med"},{"key":"1487_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","volume":"9","author":"M Certo","year":"2006","unstructured":"Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9:351\u201365.","journal-title":"Cancer Cell"},{"key":"1487_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrc2297","volume":"8","author":"AG Letai","year":"2008","unstructured":"Letai AG. Diagnosing and exploiting cancer\u2019s addiction to blocks in apoptosis. Nat Rev Cancer. 2008;8:121\u201332.","journal-title":"Nat Rev Cancer"},{"key":"1487_CR15","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.1206727","volume":"334","author":"T Ni Chonghaile","year":"2011","unstructured":"Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore VdelG, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011;334:1129\u201333.","journal-title":"Science"},{"key":"1487_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ymeth.2013.04.006","volume":"61","author":"J Ryan","year":"2013","unstructured":"Ryan J, Letai A. BH3 profiling in whole cells by fluorimeter or FACS. Methods. 2013;61:156\u201364.","journal-title":"Methods"},{"key":"1487_CR17","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/leu.2015.184","volume":"30","author":"C Touzeau","year":"2016","unstructured":"Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile TN, Le Gouill S, et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016;30:761\u20134.","journal-title":"Leukemia"},{"key":"1487_CR18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1515\/hsz-2016-0107","volume":"397","author":"J Ryan","year":"2016","unstructured":"Ryan J, Montero J, Rocco J, Letai A. iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. Biol Chem. 2016;397:671\u20138.","journal-title":"Biol Chem"},{"key":"1487_CR19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/s41418-019-0391-9","volume":"27","author":"M Villalobos-Ortiz","year":"2020","unstructured":"Villalobos-Ortiz M, Ryan J, Mashaka TN, Opferman JT, Letai A. BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics. Cell Death Differ. 2020;27:999\u20131007.","journal-title":"Cell Death Differ"},{"key":"1487_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38552-z","volume":"14","author":"DS Potter","year":"2023","unstructured":"Potter DS, Du R, Bohl SR, Chow KH, Ligon KL, Bueno R, et al. Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma. Nat Commun. 2023;14:2897.","journal-title":"Nat Commun"},{"key":"1487_CR21","doi-asserted-by":"crossref","unstructured":"Rigo A, Vaisitti T, Laudanna C, Terrabuio E, Micillo M, Frusteri C, et al. Decreased apoptotic priming and loss of BCL-2 dependence are functional hallmarks of Richter's syndrome. Cell Death Dis 2024,15:323.","DOI":"10.1038\/s41419-024-06707-5"},{"key":"1487_CR22","doi-asserted-by":"crossref","unstructured":"Kytola S, Vanttinen I, Ruokoranta T, Partanen A, Holopainen A, Saad J, et al. Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial. Blood 2025;145:409\u201321.","DOI":"10.1182\/blood.2024024968"},{"key":"1487_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538:477\u201382.","journal-title":"Nature"},{"key":"1487_CR24","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1021\/acsmedchemlett.9b00568","volume":"11","author":"L Wang","year":"2020","unstructured":"Wang L, Doherty GA, Judd AS, Tao ZF, Hansen TM, Frey RR, et al. Discovery of A-1331852, a first-in-class, potent, and orally-bioavailable BCL-X(L) inhibitor. ACS Med Chem Lett. 2020;11:1829\u201336.","journal-title":"ACS Med Chem Lett"},{"key":"1487_CR25","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1182\/blood-2012-02-414060","volume":"120","author":"MS Davids","year":"2012","unstructured":"Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ, et al. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood. 2012;120:3501\u20139.","journal-title":"Blood"},{"key":"1487_CR26","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","volume":"127","author":"MA Anderson","year":"2016","unstructured":"Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127:3215\u201324.","journal-title":"Blood"},{"key":"1487_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138.","journal-title":"Nat Med"},{"key":"1487_CR28","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","volume":"8","author":"HE Ramsey","year":"2018","unstructured":"Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8:1566\u201381.","journal-title":"Cancer Discov"},{"key":"1487_CR29","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-19-1397","volume":"26","author":"X Yi","year":"2020","unstructured":"Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, et al. AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia. Clin Cancer Res. 2020;26:3856\u201367.","journal-title":"Clin Cancer Res"},{"key":"1487_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/bjh.12457","volume":"163","author":"M Vogler","year":"2013","unstructured":"Vogler M, Dinsdale D, Dyer MJ, Cohen GM. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol. 2013;163:139\u201342.","journal-title":"Br J Haematol"},{"key":"1487_CR31","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/bjc.2016.49","volume":"114","author":"M Butterworth","year":"2016","unstructured":"Butterworth M, Pettitt A, Varadarajan S, Cohen GM. BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells. Br J Cancer. 2016;114:638\u201341.","journal-title":"Br J Cancer"},{"key":"1487_CR32","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1097-2765(00)00136-2","volume":"6","author":"T Lindsten","year":"2000","unstructured":"Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA, et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell. 2000;6:1389\u201399.","journal-title":"Mol Cell"},{"key":"1487_CR33","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1126\/science.1059108","volume":"292","author":"MC Wei","year":"2001","unstructured":"Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001;292:727\u201330.","journal-title":"Science"},{"key":"1487_CR34","first-page":"1253","volume":"109","author":"RA Pan","year":"2023","unstructured":"Pan RA, Wang Y, Qiu S, Villalobos-Ortiz M, Ryan J, Morris E, et al. BH3 profiling as pharmacodynamic biomarker for the activity of BH3 mimetics. Haematologica. 2023;109:1253\u20138.","journal-title":"Haematologica"},{"key":"1487_CR35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","volume":"17","author":"L Chen","year":"2005","unstructured":"Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17:393\u2013403.","journal-title":"Mol Cell"},{"key":"1487_CR36","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.molcel.2005.02.003","volume":"17","author":"T Kuwana","year":"2005","unstructured":"Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell. 2005;17:525\u201335.","journal-title":"Mol Cell"},{"key":"1487_CR37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1083\/jcb.200708096","volume":"180","author":"EF Lee","year":"2008","unstructured":"Lee EF, Czabotar PE, van Delft MF, Michalak EM, Boyle MJ, Willis SN, et al. A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J Cell Biol. 2008;180:341\u201355.","journal-title":"J Cell Biol"},{"key":"1487_CR38","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1021\/cb500340w","volume":"9","author":"GW Foight","year":"2014","unstructured":"Foight GW, Ryan JA, Gulla SV, Letai A, Keating AE. Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. ACS Chem Biol. 2014;9:1962\u20138.","journal-title":"ACS Chem Biol"},{"key":"1487_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1535-6108(02)00127-7","volume":"2","author":"A Letai","year":"2002","unstructured":"Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002;2:183\u201392.","journal-title":"Cancer Cell"},{"key":"1487_CR40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1101\/sqb.2016.81.030841","volume":"81","author":"DS Potter","year":"2016","unstructured":"Potter DS, Letai A. To prime, or not to prime: that is the question. Cold Spring Harb Symp Quant Biol. 2016;81:131\u201340.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"1487_CR41","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2016-03-704908","volume":"128","author":"JN Gong","year":"2016","unstructured":"Gong JN, Khong T, Segal D, Yao Y, Riffkin CD, Garnier JM, et al. Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood. 2016;128:1834\u201344.","journal-title":"Blood"},{"key":"1487_CR42","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1128\/MCB.22.11.3577-3589.2002","volume":"22","author":"M Marani","year":"2002","unstructured":"Marani M, Tenev T, Hancock D, Downward J, Lemoine NR. Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis. Mol Cell Biol. 2002;22:3577\u201389.","journal-title":"Mol Cell Biol"},{"key":"1487_CR43","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/blood-2018-03-836718","volume":"132","author":"P Gomez-Bougie","year":"2018","unstructured":"Gomez-Bougie P, Maiga S, Tessoulin B, Bourcier J, Bonnet A, Rodriguez MS, et al. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. Blood. 2018;132:2656\u201369.","journal-title":"Blood"},{"key":"1487_CR44","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1182\/bloodadvances.2019000702","volume":"3","author":"A Slomp","year":"2019","unstructured":"Slomp A, Moesbergen LM, Gong JN, Cuenca M, von dem Borne PA, Sonneveld P, et al. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. Blood Adv. 2019;3:4202\u201314.","journal-title":"Blood Adv"},{"key":"1487_CR45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/leu.2017.243","volume":"32","author":"TC Teh","year":"2018","unstructured":"Teh TC, Nguyen NY, Moujalled DM, Segal D, Pomilio G, Rijal S, et al. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia. 2018;32:303\u201312.","journal-title":"Leukemia"},{"key":"1487_CR46","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","volume":"33","author":"DM Moujalled","year":"2019","unstructured":"Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia. 2019;33:905\u201317.","journal-title":"Leukemia"},{"key":"1487_CR47","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0076-6879(09)05020-4","volume":"457","author":"IR Lanza","year":"2009","unstructured":"Lanza IR, Nair KS. Functional assessment of isolated mitochondria in vitro. Methods Enzymol. 2009;457:349\u201372.","journal-title":"Methods Enzymol"},{"key":"1487_CR48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/bs.mcb.2019.10.002","volume":"155","author":"PC Liao","year":"2020","unstructured":"Liao PC, Bergamini C, Fato R, Pon LA, Pallotti F. Isolation of mitochondria from cells and tissues. Methods Cell Biol. 2020;155:3\u201331.","journal-title":"Methods Cell Biol"},{"key":"1487_CR49","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood.2019004326","volume":"136","author":"MV Haselager","year":"2020","unstructured":"Haselager MV, Kielbassa K, Ter Burg J, Bax DJC, Fernandes SM, Borst J, et al. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood. 2020;136:2918\u201326.","journal-title":"Blood"},{"key":"1487_CR50","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Guieze","year":"2019","unstructured":"Guieze R, Liu VM, Rosebrock D, Jourdain AA, Hernandez-Sanchez M, Martinez Zurita A, et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019;36:369\u2013384.e313.","journal-title":"Cancer Cell"},{"key":"1487_CR51","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2022016040","volume":"140","author":"R Thijssen","year":"2022","unstructured":"Thijssen R, Tian L, Anderson MA, Flensburg C, Jarratt A, Garnham AL, et al. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy. Blood. 2022;140:2127\u201341.","journal-title":"Blood"},{"key":"1487_CR52","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1182\/blood.2021014304","volume":"140","author":"D Thomalla","year":"2022","unstructured":"Thomalla D, Beckmann L, Grimm C, Oliverio M, Meder L, Herling CD, et al. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood. 2022;140:2113\u201326.","journal-title":"Blood"},{"key":"1487_CR53","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1182\/blood.2022016600","volume":"142","author":"JK Khalsa","year":"2023","unstructured":"Khalsa JK, Cha J, Utro F, Naeem A, Murali I, Kuang Y, et al. Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples. Blood. 2023;142:421\u201333.","journal-title":"Blood"},{"key":"1487_CR54","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/nar\/gku749","volume":"42","author":"AM Kabadi","year":"2014","unstructured":"Kabadi AM, Ousterout DG, Hilton IB, Gersbach CA. Multiplex CRISPR\/Cas9-based genome engineering from a single lentiviral vector. Nucleic Acids Res. 2014;42:e147.","journal-title":"Nucleic Acids Res"},{"key":"1487_CR55","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.celrep.2015.02.002","volume":"10","author":"BJ Aubrey","year":"2015","unstructured":"Aubrey BJ, Kelly GL, Kueh AJ, Brennan MS, O\u2019Connor L, Milla L, et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep. 2015;10:1422\u201332.","journal-title":"Cell Rep."},{"key":"1487_CR56","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","volume":"26","author":"CI Bliss","year":"2008","unstructured":"Bliss CI. The toxicity of poisons applied jointly1. Ann Appl Biol. 2008;26:585\u2013615.","journal-title":"Ann Appl Biol"},{"key":"1487_CR57","doi-asserted-by":"publisher","first-page":"279ra240","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015;7:279ra240.","journal-title":"Sci Transl Med"},{"key":"1487_CR58","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","volume":"128","author":"SL Khaw","year":"2016","unstructured":"Khaw SL, Suryani S, Evans K, Richmond J, Robbins A, Kurmasheva RT, et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood. 2016;128:1382\u201395.","journal-title":"Blood"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01487-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01487-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01487-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:28:35Z","timestamp":1757161715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01487-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1487"],"URL":"https:\/\/doi.org\/10.1038\/s41418-025-01487-7","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"5 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JNG, TMD, DMM, GP, MAA, CDR, CAW, GL, MJH, A Strasser, AHW, MFvD, AWR and DCSH are former or current employees of the Walter and Eliza Hall Institute which receives milestone and royalty payments related to venetoclax. AWR has received research funding from AbbVie. DCSH has received research funding from Genentech and Servier.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Peripheral blood or bone marrow samples were collected from patients after written informed consent was obtained. Studies were performed with the approval of the institutional Human Research Ethics Committees at WEHI (approval 05\/04), the Royal Melbourne Hospital, the Monash Medical Centre, or the Alfred Hospital. All animal experimentation was approved by the Walter and Eliza Hall Institute Animal Ethics Committee (AEC approval 2017.007) and conducted according to its guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}